The BioPharm Brief: Myeloma, Hemophilia, and KRAS

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

In today’s brief, we cover three updates and three different paths to progress, including easier dosing in multiple myeloma, broader access in hemophilia, and a billion-dollar bet on KRAS-targeted oncology.

Sanofi has received European Commission approval for a subcutaneous formulation of isatuximab, marketed as Sarclisa, across its existing multiple myeloma indications. The approval gives patients a shorter administration option compared with intravenous infusion, reflecting a broader industry trend toward more convenient oncology treatments that can reduce time spent in the clinic while maintaining established efficacy and safety profiles.

In rare disease news, the FDA has expanded the approval of Pfizer's Hympavzi to include pediatric patients ages 6 to 11 years and people with hemophilia A or B who have inhibitors. The decision broadens access to the once-weekly subcutaneous therapy and marks the first non-factor subcutaneous treatment available for children ages 6 to 11 years with hemophilia B. The approval was supported by Phase 3 data showing substantial reductions in bleeding rates across multiple patient populations.

And in oncology business development, Johnson & Johnson has agreed to acquire Firefly Bio for $1 billion. The deal gives J&J access to Firefly's Firelink platform, a technology designed to deliver protein-degrading therapies directly to cancer cells. The acquisition reflects continued interest in targeted protein degradation and the pursuit of new approaches for KRAS-driven cancers, which remain among the most challenging targets in oncology drug development.

Today's stories highlight three recurring themes in biopharma: improving treatment convenience, expanding options for underserved patient populations, and investing in next-generation technologies that could shape future drug pipelines.

That's all for today's BioPharm Brief. For further analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• Myeloma gets more convenient: Sanofi's subcutaneous Sarclisa could reduce treatment burden for multiple myeloma patients across approved indications.
• Hemophilia options expand: Pfizer's HYMPAVZI gains access to younger patients and those with inhibitors, addressing areas of significant unmet need.
• A billion-dollar bet on KRAS: Johnson & Johnson is acquiring Firefly Bio to strengthen its oncology pipeline with targeted protein degradation technology.